Trial Outcomes & Findings for [Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression] (NCT NCT05551195)
NCT ID: NCT05551195
Last Updated: 2025-02-24
Results Overview
Measure of depression. This is a 6-item questionnaire, where total scores range from 0 to 22, with higher scores indicating greater severity of depression.
TERMINATED
NA
7 participants
Change from Baseline to Post-treatment at Week 8
2025-02-24
Participant Flow
Participant milestones
| Measure |
WB001 With Adjunctive Treatment as Usual
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Overall Study
STARTED
|
1
|
6
|
|
Overall Study
COMPLETED
|
1
|
6
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]
Baseline characteristics by cohort
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=6 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
Total
n=7 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
1 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States · New York (Northeast)
|
1 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Region of Enrollment
United States · Florida (Southeast)
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Region of Enrollment
United States · California (West)
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Change from Baseline to Post-treatment at Week 8Population: One participant missing data at Week 8
Measure of depression. This is a 6-item questionnaire, where total scores range from 0 to 22, with higher scores indicating greater severity of depression.
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=5 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Hamilton Rating Scale for Depression (HAM-D)
|
0 score on a scale
Standard Deviation 0
|
-5.4 score on a scale
Standard Deviation 3.36
|
SECONDARY outcome
Timeframe: Change Baseline to Post-treatment at Week 8Measure of postpartum depression. A 10-item self-report questionnaire that assesses depression criteria and yields a total score from 0 to 30 where higher scores denote greater depression.
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=6 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Edinburgh Postpartum Depression Scale (EPDS)
|
0 score on a scale
Standard Deviation 0
|
-6.83 score on a scale
Standard Deviation 6.37
|
SECONDARY outcome
Timeframe: Change Baseline to Post-treatment at Week 8Measure of depression. A 9-item self-report questionnaire where total scores range from 0 to 27, with higher scores indicating greater levels of depression
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=6 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Patient Health Questionnaire (PHQ-9)
|
-3 score on a scale
Standard Deviation 0
|
-8.17 score on a scale
Standard Deviation 6.18
|
SECONDARY outcome
Timeframe: Change from Baseline to Post-treatment at Week 8Measure of anxiety. A 7-item brief self-report questionnaire, where total score range is between 0-21, with higher scores indicate greater levels of anxiety.
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=6 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Generalized Anxiety Disorder Questionnaire (GAD-7)
|
1 score on a scale
Standard Deviation 0
|
-6.33 score on a scale
Standard Deviation 2.88
|
SECONDARY outcome
Timeframe: Change from Baseline to Post-treatment at Week 8Measure of mother-infant bond. An 8-item self-report questionnaire, where total scores range from 0 to 24, with lower scores indicating good bonding.
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=6 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Mother-to-Infant Bonding Scale (MIBS)
|
-2 score on a scale
Standard Deviation 0
|
0.17 score on a scale
Standard Deviation 2.40
|
SECONDARY outcome
Timeframe: Change Baseline to Post-treatment at Week 8Measure of overall severity of current clinical presentation and symptomatology. A single item, 7-point Likert scale on which the investigator will rate patients' severity of illness based on clinical interviews and assessments relative to their experience with other patients with the same diagnosis. Responses include 0 (not assessed) and range from 1 (Normal, not at all ill) to 7 (Among the most extremely ill).
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=6 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Clinical Global Impressions Scale - Severity of Illness (CGI-S)
|
0 score on a scale
Standard Deviation 0
|
-1.50 score on a scale
Standard Deviation 0.84
|
SECONDARY outcome
Timeframe: Change from Mid-treatment at Week 4 to Post-treatment at Week 8Measure of improvement. A single item, 7-point Likert scale that assesses the overall improvement in patients' condition at the end of treatment. The investigator will rate whether the participant's total improvement was due entirely to the intervention. Responses include 0 (not assessed) and range from 1 (very much improved) to 7 (very much worse).
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=6 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Clinical Global Impressions Scale - Global Improvement (CGI-I)
|
0 score on a scale
Standard Deviation 0
|
-1.17 score on a scale
Standard Deviation 0.98
|
SECONDARY outcome
Timeframe: PGI-S: Change from Baseline to Post-treatment at Week 8; PGI-C: Change from Mid-treatment at Week 4 to Post-treatment at Week 8Measure of change in clinical status. A single item scale based on the CGI and adapted to the patient that mainly measures change in clinical status (PGI-C) but can also measure disease severity (PGI-S) or disease improvement (PGI-I). PGI-S responses for current illness severity range from "I Feel Fine (1)" to "I Feel Extremely Ill (4)". PGI-C responses range from "Very Much Improved (1) to "Very Much Worse (7)" since starting the trial. For both scales, lower scores indicate better outcomes.
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=6 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Patient Global Impression Scale (PGI)
PGI-S
|
1 score on a scale
Standard Deviation 0
|
-0.67 score on a scale
Standard Deviation 1.21
|
|
Patient Global Impression Scale (PGI)
PGI-C
|
1 score on a scale
Standard Deviation 0
|
-1 score on a scale
Standard Deviation 0.63
|
SECONDARY outcome
Timeframe: Post-treatment at Week 8Population: One participant did not complete the CSQ-8
An 8-item measure used to assess client's satisfaction with treatment.Total scores range from 8-32, with high scores indicating greater satisfaction with the treatment.
Outcome measures
| Measure |
WB001 With Adjunctive Treatment as Usual
n=1 Participants
Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
WB001: WB001 is a digital therapeutic for postpartum depression.
|
Educational Control (ED001) With Adjunctive Treatment as Usual
n=5 Participants
Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
ED001: ED001 is a digital therapeutic for postpartum depression.
|
|---|---|---|
|
Client Satisfaction Questionnaire (CSQ-8)
|
17 score on a scale
Standard Deviation 0
|
29 score on a scale
Standard Deviation 4.64
|
Adverse Events
WB001 With Adjunctive Treatment as Usual
Educational Control (ED001) With Adjunctive Treatment as Usual
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60